Nippon Shinyaku Co., Ltd. (NPNKF)
OTCMKTS · Delayed Price · Currency is USD
25.58
0.00 (0.00%)
Aug 12, 2025, 8:00 PM EDT
Nippon Shinyaku Revenue
Nippon Shinyaku had revenue of 39.55B JPY in the quarter ending June 30, 2025, with 1.06% growth. This brings the company's revenue in the last twelve months to 160.65B, up 6.83% year-over-year. In the fiscal year ending March 31, 2025, Nippon Shinyaku had annual revenue of 160.23B with 8.08% growth.
Revenue (ttm)
160.65B JPY
Revenue Growth
+6.83%
P/S Ratio
1.34
Revenue / Employee
71.62M JPY
Employees
2,243
Market Cap
1.49B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 160.23B | 11.98B | 8.08% |
Mar 31, 2024 | 148.26B | 4.08B | 2.83% |
Mar 31, 2023 | 144.18B | 6.69B | 4.87% |
Mar 31, 2022 | 137.48B | 15.60B | 12.80% |
Mar 31, 2021 | 121.89B | 5.25B | 4.50% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 84.04M |
Glass House Brands | 215.62M |
American Oncology Network | 1.76B |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.17M |
BioStem Technologies | 332.45M |